Department of Otorhinolaryngology, Head & Neck Surgery, Yan Chai Hospital, Hong Kong Special Administrative Region, People's Republic of China.
Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, People's Republic of China.
J Med Virol. 2018 Jun;90(6):1150-1159. doi: 10.1002/jmv.25058. Epub 2018 Mar 6.
To delineate the role of human papillomavirus (HPV) in laryngeal cancer in Southern Chinese, a retrospective cross-sectional study was conducted in a major otorhinolaryngology referral center in Hong Kong. Eighty-five Chinese patients with histology-confirmed laryngeal squamous cell carcinoma (LSCC) diagnosed between 2005 and 2010 were examined for the status of HPV by PCR, and the expression of p16 and p53 by immunohistochemistry. The HPV, p16 and p53 findings were correlated with clinicopathological features, recurrence and 5-year survival. HPV DNA was detected in one patient (1.2%, 95%CI: 0.2-6.4%) who had glottic cancer and harbored HPV-6. Overexpression of p16 and p53 were detected in 11 (12.9%) and 47 (55.3%) cases, respectively. Recurrence occurred in 22.4% of patients at a median of 13 months. The 5-year overall survival and disease-specific survival were 55.7% and 72.4%, respectively. Overexpression of p16 or p53 was not associated with clinicopathological features, recurrence or overall survival. HPV plays a limited role in laryngeal cancer in Hong Kong Southern Chinese. In contrast to oropharyngeal cancer, p16 cannot be used as a surrogate marker for oncogenic involvement of HPV and cannot predict survival in laryngeal cancer.
为了阐明人乳头瘤病毒(HPV)在华南地区喉癌中的作用,我们在香港一家主要的耳鼻喉科转诊中心进行了一项回顾性的横断面研究。对 85 例经组织学证实的喉鳞状细胞癌(LSCC)患者的 HPV 状态进行了 PCR 检测,并通过免疫组化检测了 p16 和 p53 的表达情况。HPV、p16 和 p53 的发现与临床病理特征、复发和 5 年生存率相关。一名患有声门型癌症且携带 HPV-6 的患者(1.2%,95%CI:0.2-6.4%)中检测到 HPV DNA。11 例(12.9%)和 47 例(55.3%)患者的 p16 和 p53 过表达分别为 11 例和 47 例。患者中有 22.4%在中位时间为 13 个月时复发。5 年总生存率和疾病特异性生存率分别为 55.7%和 72.4%。p16 或 p53 的过表达与临床病理特征、复发或总生存率无关。HPV 在香港南部中国人的喉癌中起有限作用。与口咽癌不同,p16 不能作为 HPV 致癌作用的替代标志物,也不能预测喉癌的生存率。